Hossein A. Ghanbari, Ph. D., is co-founder of Panacea Pharmaceuticals and serves as its Chief Executive Officer, Chief Scientific Officer, and Chairman of the Board. The company has developed tests for prostate cancer, breast cancer, lung cancer, and colorectal cancer. The lung cancer test was selected as a Top 10 Medical Breakthrough by Time magazine. Panacea has three preclinical drug candidates for cancer and one for treating neural damage and neurodegeneration. At Abbott Laboratories in Chicago, Dr. Ghanbari developed several pharmaceuticals including Leupron (for prostate cancer) and Survanta (for respiratory distress syndrome), along with the first ever commercialized diagnostic test for Alzheimer’s disease. Dr. Ghanbari was inducted into the prestigious honorary organization, the Volwiler Society. He held professorships at Pennsylvania State University, University of Florida, and Arya-Mehr University of Technology. He was also on the academic staff of The George Washington University School of Medicine and Health Sciences as an Adjunct Professor. Dr. Ghanbari serves as a Board member of the Gastric Cancer Foundation. He received his bachelor of sciences degree, with distinction, from the American University in Beirut, and his doctorate degree in Biochemistry from Pennsylvania State University, has authored over 60 peer reviewed publications, and is an inventor on over 60 patents and patent applications.
Source: IAAP[learn_more caption=”Dr. Ghanbari’s Lecture” state=”open”] Dr. Ghanbari’s Lecture in IAAP[/learn_more]